A s growing and converging epidemics, atrial fibrillation (AF) and heart failure (HF) together portend a worse prognosis than either condition alone. [1] [2] [3] [4] In addition, the high risk of ischemic stroke has the potential to further accelerate morbidity for these patients. 5 Though oral anticoagulation (OAC) with warfarin has the ability to reduce stroke risk significantly and has long been recommended in the American College of Cardiology/American Heart Association HF management guidelines, 6, 7 use of OAC among patients with AF and HF has historically remained insufficient (65%) in potentially eligible patients despite attempts to promote guideline adherence. 8 Recent clinical trials have shown direct oral anticoagulants (DOACs) to be equivalent or more efficacious than warfarin for AF stroke prevention, with improved safety profiles and greater ease of use. 9 Additionally, AF coexists across the HF left ventricular ejection fraction (EF) spectrum, with prior evidence suggesting that cardiovascular outcomes after AF may differ by HF subtype. 10, 11 In this study, using data from the Get With The Guidelines-Atrial Fibrillation (GWTG-AFIB) registry, we examined the clinical characteristics and rate of OAC in patients hospitalized with AF across the HF left ventricular EF spectrum and in a setting of wider availability of DOACs. In addition, we assessed factors associated with appropriate OAC in this population.
METHODS
The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.
Data Source
This study used data collected through GWTG-AFIB registry, an ongoing observational, national, inpatient, prospective quality improvement initiative started in 2013 by the American Heart Association. The program objectives, design, and data elements have been previously described. 12 One primary goal of the registry is to provide active interventions on an institution or health system level to promote rapid-cycle quality improvement. GWTG-AFIB promoted a multifaceted approach, including education and outreach, integrated decision support, and ongoing data assessment and feedback geared towards specific institutional change.
Systematic data acquisition was key. Briefly, the registry included consecutive patients aged ≥18 years who were hospitalized with a principal or secondary diagnosis of AF or atrial flutter (henceforth included together as AF). Trained personnel at participating hospitals used an online, interactive Patient Management Tool (QuintilesIMS, Cambridge, MA) for concurrent, as well as retrospective, data collection. Collected data included demographics, medical history, medications (including specific antiarrhythmic, anticoagulant, and antiplatelet agents), laboratory data, in-hospital care and procedures specifically related to AF, rate or rhythm strategy, in-hospital outcomes, discharge medications (including contraindications for evidence-based therapies), discharge status, and risk reduction interventions supported by current specialty society guidelines. Contraindications were chosen from a prepopulated list, and >1 contraindication could be selected. Included in the data collected was assessment of the CHA 2 DS 2 -VASc and HAS-BLED scores in the evaluation of thromboembolic and bleeding risk, respectively. 13, 14 The CHA 2 DS 2 -VASc score assesses a point score based on the presence of congestive HF, hypertension, age ≥65 years, diabetes mellitus, female sex, and vascular disease (prior myocardial infarction, peripheral vascular disease, or aortic plaque) with additional points given for prior stroke or transient ischemic attack and age ≥75 years. In current American College of Cardiology/American Heart Association guidelines, anticoagulation is recommended for patients with AF and a CHA 2 DS 2 -VASc score ≥2. 5 Prior HF guidelines have recommended OAC in all HF patients with AF regardless of overall CHA 2 DS 2 -VASc score. 15 The HAS-BLED score incorporates the risk of bleeding from several risk factors (hypertension, renal disease, liver disease, prior stroke, prior major bleeding or risk of bleeding, labile international normalized ratio, age >65 years, medication usage predisposing to bleeding, and heavy alcohol use), but guidelines do not recommend withholding anticoagulation based on any risk score. 5 Select hospital variables are also available, including total number of beds, US census region, rural/urban status, self-reported teaching versus nonteaching status, and presence or absence of board-certified electrophysiologists on staff.
All participating hospitals were required to comply with local regulatory and privacy guidelines and, if required, to secure institutional review board approval. Because data were used primarily at the local site for quality improvement, sites were granted a waiver of informed consent under the common rule. IQVIA (Parsippany, NJ) is the data collection coordination center for the American Heart Association/American Stroke Association GWTG programs. The Duke Clinical Research Institute (Durham, NC) serves as the data analysis center, and institutional review board approval was granted to analyze aggregate deidentified data for research purposes.
WHAT IS NEW?
• Guidelines strongly recommend use of oral anticoagulation for stroke prophylaxis in patients with atrial fibrillation and heart failure, but prior studies have shown significant gaps in medication use • In the setting of a quality improvement initiative and availability of contemporary direct oral anticoagulants, we show that there was nearly universal prescription of stroke prophylaxis among patients with atrial fibrillation and heart failure WHAT ARE THE CLINICAL IMPLICATIONS?
• These results support the use of systematic, scalable quality improvement initiatives to help implement evidence-based therapies into clinical care
Study Design and Outcomes
For this analysis, we considered and included GWTG-AFIB participants hospitalized between January 2013 and March 2017 with documentation on concurrent diagnosis or history of HF and discharge disposition ( Figure 1 ). HF was determined based on past medical history, primary diagnosis for hospitalization, or first detection during the concurrent hospital admission. Quantitative or qualitative EF, when available, was submitted by sites based on chart review. From an initial 11 536 patients from 90 hospitals, we further excluded 653 patients without documentation of EF. There were 1790 patients who had a listed contraindication to anticoagulation; these patients were described but not included in the primary analysis. The final overall study population included 9093 admissions from 89 sites, subdivided into 3 groups by EF: HF with preserved EF (HFpEF, EF≥50% or qualitative description of normal or mild ventricular dysfunction), HF with borderline EF (40%<EF<50%), and HF with reduced EF (HFrEF, EF≤40% or qualitative description of moderate/severe ventricular dysfunction).
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The primary outcome of interest was use of an oral anticoagulant at discharge among eligible patients with a history of HF without documented contraindications. Other secondary analyses were planned to determine whether OAC varied according to EF groups, direct OAC versus warfarin therapy, risk stratification by CHA 2 DS 2 -VASc and HAS-BLED scores, and other factors associated with OAC at discharge.
Statistical Analysis
We reported descriptive statistics for baseline patient and hospital characteristics for HF patients by EF group using Pearson χ 2 tests for binary or nominal categorical variables and the Kruskal-Wallis test for continuous or ordinal categorical variables. Proportions and medians with interquartile ranges were reported for categorical and continuous variables, respectively. Percent standardized differences (calculated as the difference in means or proportions divided by a pooled estimate of the SD×100) were also calculated; a standardized difference >10 is typically considered meaningful and may be useful in the interpretation of statistically significant differences that are of small clinical significance. Patient characteristics with <25% missing were imputed before entering into models. Patient medical history or medication before admission were imputed to No because we assume it was not checked when none applied. Other patient variables were imputed using multiple imputations with 25 datasets. Patient's rate/rhythm strategy was not imputed. Hospital variables were not imputed. Variable missing rates and more imputation details can be found in Table I in the Data Supplement. We used adjusted logistic regression models to evaluate covariates associated with anticoagulation at discharge among patients who were anticoagulation naive on admission. Generalized estimating equations were used to adjust for the clustering of patients within hospitals. Candidate variable selection was based on patients' key baseline demographics and clinical experience. The covariates This figure displays the initial study population, through exclusions, to the final study population. AC indicates anticoagulant; AF, atrial fibrillation; AMA, against medical advice; EF, ejection fraction; and HF, heart failure.
included were age, sex, race, insurance status, geographic region, hospital type, hospital size, rural status, adult cardiac electrophysiology site, AF type, anemia, coronary artery disease, prior stroke or transient ischemic attack, diabetes mellitus, chronic dialysis, HF, hypertension, liver disease, obstructive sleep apnea, peripheral vascular disease, chronic obstructive pulmonary disease, prior hemorrhage or bleeding, prior myocardial infarction, prior history of percutaneous intervention, smoking status, thyroid disease, HF medications before admission, aspirin and antiplatelet before admission, estimated glomerular filtration rate, body mass index, and rate versus rhythm control strategy. Adult cardiac electrophysiology site was defined as presence of board-certified adult electrophysiologist or availability of AF ablation on site. OAC use was also presented across hospital sites, and by CHA 2 DS 2 -VASc and HAS-BLED scores in figures. Because some contraindications may be viewed as more relative than absolute, we also conducted a sensitivity analysis that examined the variables associated with OAC excluding physician preference and frequent falls/frailty as contraindications. All statistical tests were 2-tailed, with P≤0.05 considered statistically significant. All analyses were performed using SAS software, version 9.4 (SAS Institute, Cary, NC).
RESULTS

Baseline Characteristics
Among 10 883 patient hospitalizations with AF and HF with documented EF, 1790 (16.4%) had a reported contraindication to anticoagulation. High bleeding risk and frequent falls/frailty were the 2 most prevalent reasons, reported in 51% of those with listed contraindications (Table 1 
OAC at Discharge
Among eligible patients with AF and HF, 94.9% of patients were prescribed OAC at discharge, with 43.6% discharged on warfarin and 50.7% discharged on a DOAC (Table 3) . Patients with HFpEF were slightly more likely to not receive OAC at discharge (5.7% versus 4.4% versus 4.6%, P=0.003). A higher proportion of patients with HFrEF and HF with borderline EF were discharged on DOAC than HFpEF, but the difference was small (52.8%, 53.1% versus 48.5%, respectively; P=0.0002). The most commonly prescribed DOAC in our population was apixaban (28% of patients prescribed OAC on discharge). Patients who were on OAC before admission were likely to have their anticoagulation prescribed at discharge (>94%). In patients who were naive to OAC (Table 4 and Table II in the Data Supplement), multivariable logistic regression identified female sex, use of ACE (angiotensin-converting enzyme) inhibitor/angiotensin receptor blocker before admission, a higher estimated glomerular filtration rate, a higher body mass index, and a rhythm control strategy as factors independently associated with higher odds of increased OAC prescription at discharge (all P<0.05). In the adjusted analysis, the EF group was not significantly associated with a patient's OAC use at discharge.
Consistent with the high overall rate of OAC prescription among eligible patients, hospital level prescription of anticoagulation was high (Figure 2) . The median rate of anticoagulation prescription among hospitals was 93.8% (interquartile range, 88.1%-97.6%), and 10 of 89 hospitals prescribed anticoagulation in all eligible patients. There was no significant association between hospital characteristics and anticoagulation prescription in eligible patients with HF and AF.
Risk Stratification and Anticoagulation Use
The median CHA 2 DS 2 -VASc score was 5 (Q1, Q3; 3, 6) among all patients and higher among those with HFpEF than HFrEF (5 [Q1, Q3; 4, 6] versus 4 [Q1, Q3; 3, 5]; P<0.001). The median HAS-BLED score was 2 (Q1, Q3; 2, 3) among all patients. As shown in Figure 3 , the highest proportion of OAC use was among patients with CHA 2 DS 2 -VASc=4. Lack of anticoagulation remained below 10% among all CHA 2 DS 2 -VASc scores. Additionally, the odds of being discharged on warfarin was 14% higher than being discharged on DOAC, for every unit increase of CHA 2 DS 2 -VASc score (odds ratio, 1.14; 95% CI, 1.11, 1.17; P<0.0001). Figure 4 shows that rates of nonanticoagulation increased with increasing bleeding risk according to the HAS-BLED risk score. Warfarin prescription also increased relative to DOAC use with increasing HAS-BLED scores (odds ratio, 1.28 for every unit increase HAS-BLED; 95% CI, 1.23, 1.33; P<0.0001) Very few patients in this population had a HAS-BLED score above 5.
Combination Antithrombotic Therapy
In the analysis population of 9093 patients, 43.2% were prescribed aspirin, with 40 Data showed number or median (Q1-Q3). Percent standardized differences are calculated as the difference in means or proportions divided by a pooled estimate of the SD×100; a standardized difference >10 is typically considered meaningful. AC indicates anticoagulant; ACE, angiotensinconverting enzyme; AF, atrial fibrillation; ARB, angiotensin receptor blocker; COPD, chronic obstructive pulmonary disease; DOAC, direct oral anticoagulants; EF, ejection fraction; eGFR, estimated glomerular filtration rate; HF, heart failure; HFbEF, HF borderline EF; HFpEF, HF preserved EF; HFrEF, HF reduced EF; HMO, health maintenance organization; LVEF, left ventricular EF; MI, myocardial infarction; NT-BNP, N-terminal pro-B-type natriuretic peptide; PCI, percutaneous coronary intervention; OAC, oral anticoagulation; and TIA, transient ischemic attack. 
Sensitivity Analyses
We excluded 2 stated contraindications to anticoagulation in a sensitivity analysis, physician preference, and frequent falls/frailty. As expected, in this increased eligible population of patients with AF and HF, stroke prophylaxis was slightly lower, prescribed in 89.6% of patients. Congruent with the main analysis, EF group was not significantly associated with OAC at discharge in adjusted models. However, increased patient age and permanent/long-standing persistent AF was now associated with significantly lower odds of OAC (Table III in the Data Supplement). Use of ACE inhibitor/angiotensin receptor blocker before admission and estimated glomerular filtration rate were no longer independently associated with OAC use, but other results were consistent with the primary analysis. Additionally, Table IV in the Data Supplement presents a comparison of how imputations for missing variables affected the multivariable modeling.
DISCUSSION
In the context of a national quality improvement initiative, we examined the characteristics and management of >9000 admissions for patients with AF and HF. In the modern era of widely available DOAC therapy, stroke prophylaxis among eligible patients with AF and HF was almost 95%, regardless of EF. To our knowledge, these rates represent some of the highest rates of appropriate anticoagulation use for patients in a national registry to date. These results strongly support the efforts of large-scale quality improvement initiatives and creation of learning health systems to Data showed number (percent) or median (Q1-Q3). Percent standardized differences are calculated as the difference in means or proportions divided by a pooled estimate of the SD×100; a standardized difference >10 is typically considered meaningful. AC indicates anticoagulant; AF, atrial fibrillation; CHA 2 DS 2 -VASc, congestive HF, hypertension, age ≥75 y (doubled), diabetes mellitus, prior stroke or transient ischemic attack or thromboembolism (doubled), vascular disease, age 65-74 y, sex category; DOAC, direct oral anticoagulants; EF, ejection fraction; HF, heart failure; HFbEF, HF borderline EF; HFpEF, HF preserved EF; HFrEF, HF reduced EF; HAS-BLED, hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly, drugs/alcohol concomitantly; and OAC, oral anticoagulation.
promote successful implementation of evidence-based care. There was no significant association between hospital characteristics and anticoagulation prescription in eligible patients with HF and AF.
Published evidence of patients in observational registries-particularly in those with HF-generally suggest that the use of stroke prophylaxis has been low. Registries in the late 1990s-2000s suggested only around 60% of eligible patients with AF received anticoagulation. 16 An earlier analysis from the GWTG-HF program data on anticoagulation between 2005 and 2008 also suggested rates of appropriate stroke prophylaxis around 65%, and no improvement over time, despite participation in a GWTG quality improvement program. 8 The rate of use of appropriate anticoagulation in outpatients treated by cardiovascular specialists in the American College of Cardiology National Cardiovascular Data Registry's Practice Innovation and Clinical Excellence Registry-a quality improvement program-between 2008 and 2012 also did not exceed 50%. 17 In contrast, in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation-a voluntary registry of US outpatients with AF-rates of OAC were generally higher at around 77%, and even higher among HF patients at 81% (irrespective of contraindications). 18, 19 In these registries, the predominant drug prescription for anticoagulation was warfarin. In the era of increasing DOAC availability and prescription, an updated analysis of the Practice Innovation and Clinical Excellence registry with data up to 2014 showed an increasing anticoagulation rate of 61%, though warfarin remained the predomi- Other covariates included in multivariable model were age, sex, race, insurance status, geographic region, hospital type, hospital size, rural status, adult cardiac electrophysiology site, AF type, anemia, coronary artery disease, prior stroke or transient ischemic attack, diabetes mellitus, chronic dialysis, HF, hypertension, liver disease, obstructive sleep apnea, peripheral vascular disease, chronic obstructive pulmonary disease, prior hemorrhage or bleeding, prior myocardial infarction, prior history of percutaneous intervention, smoking status, thyroid disease, HF medications before admission, aspirin and antiplatelet before admission, estimated glomerular filtration rate, BMI, and rate vs rhythm control strategy. Full model results included in the Data Supplement. ACE indicates angiotensin-converting enzyme; AF, atrial fibrillation; ARB, angiotensin receptor blocker; BMI, body mass index; eGFR, estimated glomerular filtration rate; HF, heart failure; HFbEF, HF borderline ejection fraction; HFpEF, HF preserved ejection fraction; HFrEF, HF reduced ejection fraction; OAC, oral anticoagulation; and OR, odds ratio. nant drug used. 20 Updated data from GWTG-HF to include 2014 also showed higher anticoagulation rates of ≈73% in patients with AF and HF. 21 Anticoagulation to prevent stroke and systemic embolism in patients with AF has been a principal target of quality improvement in AF. Compared with prior registries, use of anticoagulation in our analysis is very high. Given the voluntary nature and design of GWTG-AFIB to target quality improvement in AF care and specifically anticoagulation, some degree of bias will be inherent. Additionally, >50% of patients in the current analysis underwent AF procedures, such as cardioversion or ablation during the hospitalization, potentially heightening attention to the risk of stroke and its prevention. Nevertheless, prior work within HF has shown that focused patient data collection, targeted decision support tools, and performance feedback in a large-scale care improvement intervention can improve the use of guideline-recommended HF therapies. 22 Within GWTG-AFIB, analysis of temporal trends show sustained improvement in OAC rates over time and is also >95% in the last quarter of enrollment. 23 Prior analyses in HF and stroke have suggested variations in care and outcomes based on hospital characteristics like bed size and academic status, but we saw no significant associations between different hospital characteristics and anticoagulation prescription in eligible patients with HF and AF. 24, 25 This finding may suggest iterative improvement in the successful implementation of quality improvement methods across different hospital settings within GWTG-AFIB. Combined with increasing availability of DOACs, these data suggest concrete performance improvement techniques can have a lasting impact on promoting sustainable, evidence-based treatment.
In the primary analysis, about 16% of patients were deemed ineligible for anticoagulation because of a selected contraindication, with the most com- mon causes being frequent falls/frailty and high bleeding risk. An additional 257 of 1790 (14.9%) of patient were deemed ineligible because of patient refusal. In contrast, in the recent Practice Innovation and Clinical Excellence analysis, only 0.09% of patients had a documented contraindication to anticoagulation. 20 Our high rate of selected contraindications may be attributed to a sicker, hospitalized patient population. However, the increased accountability associated with a reportable quality metric of a quality improvement program could have contributed a significant role. Nevertheless, these contraindications reflect the challenging balance between the risk of stroke against risk of bleeding complications, especially among older patients. Prior research of elderly patients, however, suggests that their risk of ischemic stroke is greater than the risk for hemorrhagic stroke, and they may indeed derive the greatest net benefit from anticoagulation. 26, 27 Additionally, most older patients with a personal history or a perceived high risk for falls still derive net benefit from anticoagulation when balanced against the absolute risk of fall-related major bleeding. 28, 29 Thus, under a more rigorous analysis of risk versus benefit, it is likely that more of the patients excluded in the current analysis could be considered good candidates for OAC. Identifying and properly communicating risk in a shared decision model will be an important next target for quality improvement in AF management.
Our results suggest a potential mismatch in the riskbenefit assessment between DOACs and warfarin. In large clinical trials, 4 DOACs (dabigatran, rivaroxaban, apixaban, and edoxaban) consistently showed statistically lower rates of major bleeding (with the exception of rivaroxaban and dabigatran 150 mg) and intracranial bleeding when compared with warfarin. [30] [31] [32] [33] However, in our cohort, for every unit increase of HAS-BLED bleeding risk, the odds of warfarin prescription increased 28% relative to DOAC use. Risk scores, including HAS-BLED, can help quantify hemorrhage risk for individual patients, with a score ≥3 indicating high risk for bleeding. However, given their uncertain clinical utility, current practice guidelines do not make absolute recommendations based on any 1 absolute score. 5 Renal dysfunction is a component of HAS-BLED and may have contributed to the increased warfarin use. Nevertheless, recent evidence supports the safety and effectiveness of standard-dose apixaban for stroke prevention in dialysis patients with AF. 34 In appropriate patients represented by clinical trials, evidence suggests that use of DOACs may be safer in patients with a higher risk of bleeding.
The continued high use of concomitant aspirin in our cohort of patients receiving OAC remains another area for further education and improvement. Multiple prior studies have demonstrated increased risk for hemorrhage associated with combined antiplatelet and anticoagulant use in patients with appropriate indications. [35] [36] [37] [38] [39] Additionally, prior registries, such as Outcomes Registry for Better Informed Treatment have found that ≈40% of patients receiving combined therapy had no clear indication for the addition of aspirin. 39 In the current analysis, about 40% of patients were on combined aspirin and anticoagulant therapy. This finding is comparable to those described in the Outcomes Registry for Better Informed Treatment registry where 35% of the AF cohort received combined therapy and in the large apixaban and dabigatran clinical trials where ≈30% and 40% of patients, respectively, received concomitant low dose aspirin and oral anticoagulants. 30, 32 Despite increasing concerns regarding the bleeding risk of aspirin and minimal evidence of benefit in stable atherosclerotic disease, concomitant use with oral anticoagulants persists in the modern era. 37 Clinicians should further consider whether the benefits of concomitant aspirin outweigh risks in AF patients on OAC.
Study Limitations
We note several limitations of this study. First, GWTG-AFIB is a voluntary program with the explicit objective to improve adherence to guidelines for AF management and treatment in hospitalized patients. Participating hospitals may have a stronger interest in following guideline recommendations. Findings may not generalize to patients with AF and HF who are not hospitalized. However, prior analyses of other GWTG registries suggest that the patient populations are nationally representative. 40, 41 Second, patient data are collected by chart review and thus dependent on the accuracy and completeness of documentation. Additionally, patients deemed eligible for anticoagulation treatment in our analysis may have had other reasons that prevented treatment not well captured by the medical record or case report form. Lastly, postdischarge initiation or adherence and persistence to therapy is not currently available.
Conclusions
In the context of a national quality improvement initiative and of increasing DOAC availability, we found almost 95% OAC among eligible hospitalized patients with HF across the left ventricular ejection fraction spectrum and AF. Quality improvement initiatives including clinical decision support, education outreach, performance profiling, and real-time feedback can be implemented successfully with sustainable impact on patient outcomes on a national scale. In other areas of chronic AF care-such as prevention of HF, appropriate antiarrhythmic selection, and careful review of concomitant antiplatelet use-these efforts should serve as a framework for future performance improvement programs that support implementation of evidence-based care.
